がんNGSの世界市場：技術別、ワークフロー別、用途別、エンドユーザー別、地域別の分析、規模、動向、COVID-19の影響、予測（～2029年）

がんNGS（次世代シーケンシング）とは、がんの研究、診断、治療における先進のシーケンシング技術の使用を指します。NGSは、遺伝物質（DNAまたはRNA）の迅速かつ正確な解析を可能にし、がんの発生と進行を促進する遺伝子変異や変化を包括的に理解することを可能にします。2023年の世界のがんNGSの市場規模は5億1,076万米ドルであり、2029年までに11億6,670万米ドルに達すると予測されます。

世界のがんNGS市場は、複数の主な要因によって大きく成長する見通しです。世界中でのがん罹患率の増加により、正確な個別化された診断・治療ソリューションに対する需要が高まっており、NGSは包括的ながんのプロファイリングと実用的な遺伝子変異の同定を通じてこれを可能にします。精密医療とコンパニオン診断の採用の 拡大や、医療提供者と患者の意識の高まりが、市場成長をさらに促進しています。さらに、ゲノム研究への多額の投資や、がんゲノム研究を推進する政府の取り組み、リキッドバイオプシーや遺伝性がんスクリーニングなどの利用の拡大が、市場の力強い拡大に寄与しています。また、シーケンシング技術の進歩により、コストが大幅に削減され、遺伝子解析のスピードと精度が向上しています。世界のがんNGSの市場規模は、2024年～2029年の予測期間にCAGRで14.76%の成長が見込まれます。

当レポートでは、世界のがんNGS市場について調査分析し、市場力学、COVID-19の影響、競合情勢などの情報を提供しています。

目次

第1章 エグゼクティブサマリー

第2章 イントロダクション

• がんNGS：概要
  • がんNGSの定義
  • がんNGSの利点
• がんNGSのセグメンテーション：概要
  • がんNGSのセグメンテーション

第3章 世界市場の分析

• 世界のがんNGS市場：分析
  • 世界のがんNGS市場：概要
  • 世界のがんNGSの市場規模
  • 世界のがんNGS市場：技術別
  • 世界のがんNGS市場：ワークフロー別
  • 世界のがんNGS市場：用途別
  • 世界のがんNGS市場：エンドユーザー別
  • 世界のがんNGS市場：地域別
• 世界のがんNGS市場：技術の分析
  • 世界のがんNGS市場：技術別、概要
  • 世界の標的シーケンシング・リシーケンシングがんNGSの市場規模
  • 世界のエクソームシーケンシングがんNGSの市場規模
  • 世界の全ゲノムシーケンシングがんNGSの市場規模
• 世界のがんNGS市場：ワークフローの分析
  • 世界のがんNGS市場：ワークフロー別、概要
  • 世界のがんNGSシーケンシングの市場規模
  • 世界のがんNGSプレシーケンシングの市場規模別
  • 世界のがんNGSデータ解析の市場規模
• 世界のがんNGS市場：用途の分析
  • 世界のがんNGS市場：用途別、概要
  • 世界のスクリーニング用がんNGSの市場規模
  • 世界のコンパニオン診断用がんNGSの市場規模
  • 世界のその他の診断用がんNGSの市場規模
• 世界のがんNGS市場：エンドユーザーの分析
  • 世界のがんNGS市場：エンドユーザー別、概要
  • 世界の検査室向けがんNGSの市場規模
  • 世界の病院向けがんNGSの市場規模
  • 世界の診療所向けがんNGSの市場規模

第4章 地域市場の分析

• 北米のがんNGS市場：分析
  • 北米のがんNGS市場：概要
  • 北米のがんNGSの市場規模
  • 北米のがんNGS市場：地域別
  • 米国のがんNGSの市場規模
  • カナダのがんNGSの市場規模
  • メキシコのがんNGSの市場規模
• 欧州のがんNGS市場：分析
  • 欧州のがんNGS市場：概要
  • 欧州のがんNGSの市場規模
  • 欧州のがんNGS市場：地域別
  • ドイツのがんNGSの市場規模
  • 英国のがんNGSの市場規模
  • フランスのがんNGSの市場規模
  • スペインのがんNGSの市場規模
  • イタリアのがんNGSの市場規模
  • その他の欧州のがんNGSの市場規模
• アジア太平洋のがんNGS市場：分析
  • アジア太平洋のがんNGS市場：概要
  • アジア太平洋のがんNGSの市場規模
  • アジア太平洋のがんNGS市場：地域別
  • 中国のがんNGSの市場規模
  • 日本のがんNGSの市場規模
  • インドのがんNGSの市場規模
  • 韓国のがんNGSの市場規模
  • その他のアジア太平洋のがんNGSの市場規模
• その他の地域のがんNGS市場：分析
  • その他の地域のがんNGS市場：概要
  • その他の地域のがんNGSの市場規模

第5章 COVID-19の影響

• 世界のがんNGS市場に対するCOVID-19の影響
• 世界のがんNGS市場に対するCOVID-19後の影響

第6章 市場力学

• 成長促進要因
  • がん罹患率の上昇
  • 医療費の増加
  • 政府の取り組み
  • コスト削減
• 課題
  • 複雑なデータの解析と解釈
  • 倫理とプライバシーに関する懸念
• 市場動向
  • AI、バイオインフォマティクスとの統合
  • リキッドバイオプシーのイノベーション
  • 個別化医療への注目の高まり
  • コンパニオン診断の台頭
  • シーケンシング技術の進歩
  • 研究開発投資の増加
  • NGS検査の分散化

第7章 競合情勢

第8章 企業プロファイル

• Thermo Fisher Scientific Inc.
• Agilent Technologies, Inc.
• Qiagen
• Sales by Product Group
• Illumina, Inc.
• Roche Holdings AG
• Revvity, Inc.
• Pacific Biosciences of California, Inc.
• Myriad Genetics, Inc.
• Oxford Nanopore Technologies
• BGI Group (Beijing Genomics)
• Caris Life Sciences

List of Figures

• Figure 1: Benefits of Oncology NGS
• Figure 2: Oncology NGS Segmentation
• Figure 3: Global Oncology NGS Market by Value; 2019-2023 (US$ Million)
• Figure 4: Global Oncology NGS Market by Value; 2024-2029 (US$ Million)
• Figure 5: Global Oncology NGS Market by Technology; 2023 (Percentage, %)
• Figure 6: Global Oncology NGS Market by Work Flow; 2023 (Percentage, %)
• Figure 7: Global Oncology NGS Market by Application; 2023 (Percentage, %)
• Figure 8: Global Oncology NGS Market by End User; 2023 (Percentage, %)
• Figure 9: Global Oncology NGS Market by Region; 2023 (Percentage, %)
• Figure 10: Global Targeted Sequencing & Resequencing Oncology NGS Market by Value; 2019-2023 (US$ Million)
• Figure 11: Global Targeted Sequencing & Resequencing Oncology NGS Market by Value; 2024-2029 (US$ Million)
• Figure 12: Global Whole Exome Sequencing Oncology NGS Market by Value; 2019-2023 (US$ Million)
• Figure 13: Global Whole Exome Sequencing Oncology NGS Market by Value; 2024-2029 (US$ Million)
• Figure 14: Global Whole Genome Sequencing Oncology NGS Market by Value; 2019-2023 (US$ Million)
• Figure 15: Global Whole Genome Sequencing Oncology NGS Market by Value; 2024-2029 (US$ Million)
• Figure 16: Global Oncology NGS Sequencing Market by Value; 2019-2023 (US$ Million)
• Figure 17: Global Oncology NGS Sequencing Market by Value; 2024-2029 (US$ Million)
• Figure 18: Global Oncology NGS Pre-sequencing Market by Value; 2019-2023 (US$ Million)
• Figure 19: Global Oncology NGS Pre-sequencing Market by Value; 2024-2029 (US$ Million)
• Figure 20: Global Oncology NGS Data Analysis Market by Value; 2019-2023 (US$ Million)
• Figure 21: Global Oncology NGS Data Analysis Market by Value; 2024-2029 (US$ Million)
• Figure 22: Global Screening Oncology NGS Market by Value; 2019-2023 (US$ Million)
• Figure 23: Global Screening Oncology NGS Market by Value; 2024-2029 (US$ Million)
• Figure 24: Global Companion Diagnostics Oncology NGS Market by Value; 2019-2023 (US$ Million)
• Figure 25: Global Companion Diagnostics Oncology NGS Market by Value; 2024-2029 (US$ Million)
• Figure 26: Global Other Diagnostics Oncology NGS Market by Value; 2019-2023 (US$ Million)
• Figure 27: Global Other Diagnostics Oncology NGS Market by Value; 2024-2029 (US$ Million)
• Figure 28: Global Laboratories Oncology NGS Market by Value; 2019-2023 (US$ Million)
• Figure 29: Global Laboratories Oncology NGS Market by Value; 2024-2029 (US$ Million)
• Figure 30: Global Hospitals Oncology NGS Market by Value; 2019-2023 (US$ Million)
• Figure 31: Global Hospitals Oncology NGS Market by Value; 2024-2029 (US$ Million)
• Figure 32: Global Clinics Oncology NGS Market by Value; 2019-2023 (US$ Million)
• Figure 33: Global Clinics Oncology NGS Market by Value; 2024-2029 (US$ Million)
• Figure 34: North America Oncology NGS Market by Value; 2019-2023 (US$ Million)
• Figure 35: North America Oncology NGS Market by Value; 2024-2029 (US$ Million)
• Figure 36: North America Oncology NGS Market by Region; 2023 (Percentage, %)
• Figure 37: The US Oncology NGS Market by Value; 2019-2023 (US$ Million)
• Figure 38: The US Oncology NGS Market by Value; 2024-2029 (US$ Million)
• Figure 39: Canada Oncology NGS Market by Value; 2019-2023 (US$ Million)
• Figure 40: Canada Oncology NGS Market by Value; 2024-2029 (US$ Million)
• Figure 41: Mexico Oncology NGS Market by Value; 2019-2023 (US$ Million)
• Figure 42: Mexico Oncology NGS Market by Value; 2024-2029 (US$ Million)
• Figure 43: Europe Oncology NGS Market by Value; 2019-2023 (US$ Million)
• Figure 44: Europe Oncology NGS Market by Value; 2024-2029 (US$ Million)
• Figure 45: Europe Oncology NGS Market by Region; 2023 (Percentage, %)
• Figure 46: Germany Oncology NGS Market by Value; 2019-2023 (US$ Million)
• Figure 47: Germany Oncology NGS Market by Value; 2024-2029 (US$ Million)
• Figure 48: United Kingdom Oncology NGS Market by Value; 2019-2023 (US$ Million)
• Figure 49: United Kingdom Oncology NGS Market by Value; 2024-2029 (US$ Million)
• Figure 50: France Oncology NGS Market by Value; 2019-2023 (US$ Million)
• Figure 51: France Oncology NGS Market by Value; 2024-2029 (US$ Million)
• Figure 52: Spain Oncology NGS Market by Value; 2019-2023 (US$ Million)
• Figure 53: Spain Oncology NGS Market by Value; 2024-2029 (US$ Million)
• Figure 54: Italy Oncology NGS Market by Value; 2019-2023 (US$ Million)
• Figure 55: Italy Oncology NGS Market by Value; 2024-2029 (US$ Million)
• Figure 56: Rest of Europe Oncology NGS Market by Value; 2019-2023 (US$ Million)
• Figure 57: Rest of Europe Oncology NGS Market by Value; 2024-2029 (US$ Million)
• Figure 58: Asia Pacific Oncology NGS Market by Value; 2019-2023 (US$ Million)
• Figure 59: Asia Pacific Oncology NGS Market by Value; 2024-2029 (US$ Million)
• Figure 60: Asia Pacific Oncology NGS Market by Region; 2023 (Percentage, %)
• Figure 61: China Oncology NGS Market by Value, 2019-2023 (US$ Million)
• Figure 62: China Oncology NGS Market by Value; 2024-2029 (US$ Million)
• Figure 63: Japan Oncology NGS Market by Value, 2019-2023 (US$ Million)
• Figure 64: Japan Oncology NGS Market by Value; 2024-2029 (US$ Million)
• Figure 65: India Oncology NGS Market by Value, 2019-2023 (US$ Million)
• Figure 66: India Oncology NGS Market by Value; 2024-2029 (US$ Million)
• Figure 67: South Korea Oncology NGS Market by Value, 2019-2023 (US$ Million)
• Figure 68: South Korea Oncology NGS Market by Value; 2024-2029 (US$ Million)
• Figure 69: Rest of Asia Pacific Oncology NGS Market by Value, 2019-2023 (US$ Million)
• Figure 70: Rest of Asia Pacific Oncology NGS Market by Value; 2024-2029 (US$ Million)
• Figure 71: Rest of the World Oncology NGS Market by Value; 2019-2023 (US$ Million)
• Figure 72: Rest of the World Oncology NGS Market by Value; 2024-2029 (US$ Million)
• Figure 73: Global Estimated Number of New Cases; 2022 to 2050, Males and Females (Million)
• Figure 74: The US Health Consumption Expenditure as a Percentage of GDP; 2016-2022 (Percentage, %)
• Figure 75: Global Artificial Intelligence (AI) in Healthcare Market; 2021-2030 (US$ Billion)
• Figure 76: Thermo Fisher Scientific Inc. Revenues by Segments; 2023 (Percentage, %)
• Figure 77: Agilent Technologies, Inc. Revenue by Segments; 2023 (Percentage, %)
• Figure 78: Qiagen Net Sales by Product Group; 2023 (Percentage, %)
• Figure 79: Illumina Revenue by Segments; 2023 (Percentage, %)
• Figure 80: Roche Holdings AG Sales by Operating Segment; 2023 (Percentage, %)
• Figure 81: Revvity, Inc. Revenue by Segments; 2023 (Percentage, %)
• Figure 82: Pacific Biosciences of California, Inc. Revenue by Geography; 2023 (Percentage, %)

Oncology NGS (Next-Generation Sequencing) refers to the use of advanced sequencing technologies in cancer research, diagnosis, and treatment. NGS allows for the rapid and accurate analysis of genetic material (DNA or RNA), enabling a comprehensive understanding of the genetic mutations and alterations that drive cancer development and progression. The global oncology NGS market value in 2023 stood at US$510.76 million, and is projected to reach US$1166.70 million by 2029.

The global oncology NGS market is poised for significant growth, driven by several key factors. The increasing prevalence of cancer worldwide has heightened the demand for precise and personalized diagnostic and treatment solutions, which NGS enables through comprehensive tumor profiling and identification of actionable genetic mutations. Growing adoption of precision medicine and companion diagnostics, coupled with rising awareness among healthcare providers and patients, has further fueled market growth. Additionally, substantial investments in genomic research, government initiatives to promote cancer genomics, and the expansion of applications such as liquid biopsy and hereditary cancer screening have contributed to the market's robust expansion. Advancements in sequencing technologies, have also significantly reduced costs and improved the speed and accuracy of genetic analysis. The global oncology NGS market value is projected to grow at a CAGR of 14.76%, during the forecast period of 2024-2029.

Market Segmentation Analysis:

By Technology: According to the report, the global oncology NGS market is bifurcated into three segments based on the technology: targeted sequencing & resequencing, whole exome sequencing and whole genome sequencing. Targeted sequencing & resequencing segment acquired majority of share in the market in 2023 due to its cost-effectiveness, faster processing times, and ability to focus on specific cancer-related genes, making it ideal for clinical applications such as diagnostics and personalized treatment. Its widespread adoption in research and healthcare settings further solidified its dominance. While, whole genome sequencing segment is experiencing rapid growth in the global oncology NGS market due to its capability to provide a comprehensive view of the entire genetic landscape, enabling the discovery of novel mutations and biomarkers. Additionally, its utility in studying rare or undiagnosed cancers and enabling breakthroughs in personalized medicine has accelerated its adoption.

By Workflow: According to the report, the global oncology NGS market is bifurcated into three types of workflows: NGS sequencing, NGS Pre-sequencing and NGS data analysis. NGS sequencing segment acquired majority of share in the market in 2023 due to its central role in the overall workflow, as it encompasses the actual sequencing process, which is critical for generating high-quality genomic data. The increasing adoption of advanced sequencing platforms, coupled with rising demand for accurate and efficient cancer diagnostics and treatment monitoring, further boosted its market share. While, the NGS pre-sequencing segment is experiencing rapid growth in the global oncology NGS market due to the increasing need for high-quality sample preparation. Advances in library preparation, target enrichment techniques, and automation tools have streamlined the pre-sequencing process, improved efficiency and reducing errors. Additionally, the rising complexity of oncology samples, such as liquid biopsies and heterogeneous tumors, has heightened the demand for robust pre-sequencing solutions, driving its rapid adoption in both research and clinical settings.

By Application: According to the report, the global oncology NGS market is bifurcated into three applications: screening, companion diagnostics and other diagnostics. Screening segment acquired majority of share in the market in 2023 due to the growing emphasis on early cancer detection. NGS-based screening allows for the identification of genetic mutations and biomarkers that can indicate the presence of cancer at earlier stages, enabling more effective and personalized treatment options. Whereas, companion diagnostics segment has been experiencing rapid growth in the global oncology NGS market due to its critical role in personalized medicine. The growing focus on precision oncology and the increasing approval of targeted therapies by regulatory bodies have significantly fueled the demand for companion diagnostics in cancer care.

By End User: According to the report, the global oncology NGS market is bifurcated into two end users: laboratories, hospitals and clinics. Laboratories acquired majority of share in the market in 2023 due to their essential role in conducting high-throughput sequencing and genomic testing for cancer research and diagnostics. Laboratories are equipped with advanced sequencing platforms and specialized expertise to handle large volumes of samples, offering critical insights into genetic mutations and cancer progression. Whereas, clinics segment has been experiencing rapid growth in the global oncology NGS market due to the growing trend of integrating genomic testing into routine clinical practice, along with improved patient awareness and the need for precision medicine. With advancements in NGS technology, clinics are now able to offer more efficient and accurate genetic testing, enabling early cancer detection, targeted therapies, and continuous monitoring of treatment efficacy.

By Region: The report provides insight into the oncology NGS market based on the geographical operations, namely, North America, Europe, Asia Pacific, and rest of the world. The North America oncology NGS market enjoyed the highest market share in 2023 due to the region's strong healthcare infrastructure, advanced research capabilities, and high adoption of precision medicine. The presence of leading biotechnology and pharmaceutical companies, along with significant investments in cancer genomics and diagnostics, has accelerated the use of NGS technologies in cancer treatment and research. Additionally, the growing emphasis on early cancer detection, personalized therapies, and the increasing support from government initiatives further contributed to the dominance of North America in the oncology NGS market. While, Asia Pacific region has been experiencing fastest growth in the global oncology NGS market due to increasing healthcare investments, a rising prevalence of cancer, and the expanding adoption of advanced diagnostic technologies. Rapid advancements in genomics research, along with improving healthcare infrastructure and access to NGS platforms, have driven demand for personalized cancer treatments. Additionally, growing awareness about cancer prevention and early detection, along with government initiatives to support precision medicine, are fueling the expansion of the oncology NGS market in the region. India is expected to register the fastest growth in the Asia Pacific's oncology NGS market due to the increasing burden of cancer and the rising demand for advanced diagnostic technologies. With growing investments in healthcare infrastructure, rapid adoption of precision medicine, and government initiatives to improve cancer care, India is becoming a key player in the genomics field.

Global Oncology NGS Market Dynamics:

Growth Drivers: One of the most important factors driving the growth of global oncology NGS market is rising incidences of cancer. As the global cancer burden continues to increase, early and accurate detection of genetic mutations and biomarkers becomes crucial for improving patient outcomes. NGS technologies, with their ability to provide comprehensive genomic data, enable more precise diagnoses and targeted therapies, which are essential for managing cancer more effectively. This growing demand for personalized medicine, along with the need for innovative solutions to address the rising cancer cases, has significantly accelerated the adoption of NGS in oncology, driving market growth. Other factors driving the growth of global oncology NGS market include growing healthcare expenditure, government initiatives, cost reduction etc.

Challenges: One significant challenge faced by the global oncology NGS market is the complex data analysis required to interpret the vast amounts of genomic information generated by sequencing technologies. NGS produces high-dimensional data that necessitates advanced bioinformatics tools, specialized algorithms, and expert knowledge to accurately identify relevant mutations, biomarkers, and therapeutic targets. The complexity of analyzing and integrating this data into clinical practice can lead to delays, increased costs, and the need for skilled personnel, all of which present obstacles to the widespread adoption and effective use of NGS in oncology. Another challenge might include high cost associated, etc.

Trends: Liquid biopsy innovations are a significant market trend in the global oncology NGS market, driven by the growing demand for non-invasive cancer diagnostics and monitoring. Liquid biopsies involve analyzing blood samples to detect circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), or other cancer-related biomarkers, offering a less invasive alternative to traditional tissue biopsies. This innovation enables early cancer detection, monitoring of treatment response, and detection of minimal residual disease or relapse, all without the need for complex surgical procedures. The increasing adoption of liquid biopsy technologies in clinical practice, coupled with advances in NGS platforms to analyze these samples, is propelling the growth of the oncology NGS market by offering more accessible, cost-effective, and real-time cancer diagnostics. The market is also projected to grow at a fast pace during the forecast period, due to various other latest trends such as integration with AI and Bioinformatics, increased focus on personalized medicine, rise of companion diagnostics, advancements in sequencing technologies, increased R&D investments, decentralization of NGS testing etc.

Impact Analysis of COVID-19 and Way Forward:

The COVID-19 pandemic had a significant impact on the global oncology NGS market, initially causing disruptions in cancer diagnostics and treatment due to the reallocation of healthcare resources to pandemic management and the delay of non-urgent medical procedures. Cancer screening and elective surgeries were postponed, leading to a backlog in diagnoses and treatment initiation. However, the pandemic also accelerated the adoption of telemedicine and non-invasive diagnostic tools, including liquid biopsies, which gained traction as alternatives to traditional methods. As healthcare systems recover, there is a renewed focus on addressing the backlog in cancer care and increasing investments in oncology genomics to support personalized medicine. The way forward includes leveraging digital health solutions, improving access to genomics-based testing, and fostering collaborations between healthcare providers and biotech companies to enhance early detection, treatment efficacy, and monitoring in oncology, ensuring a more resilient and efficient healthcare system.

Competitive Landscape and Recent Developments:

The global oncology NGS market is fragmented, characterized by the presence of numerous players, including established global companies, regional firms, and emerging startups. This fragmentation stems from the diverse nature of NGS applications, ranging from diagnostics to drug discovery, as well as the rapid technological advancements in sequencing technologies, bioinformatics, and data analysis tools. Key players of global oncology NGS market are:

Thermo Fisher Scientific Inc.

Agilent Technologies, Inc.

Qiagen

Illumina, Inc.

Roche Holdings AG

Revvity Inc.

Pacific Biosciences of California Inc.

Myriad Genetics Inc.

Oxford Nanopore Technologies

BGI Group (Beijing Genomics)

Caris Life Sciences

The key players are constantly investing in strategic initiatives, such as adoption of new technologies, introducing their products to emerging markets and more, to maintain a competitive edge in this market. For instance, In January 2023, Qiagen N.V. completed the acquisition of Verogen, Inc. in order to deploy next-generation biometrics for forensic and molecular testing and in April 2023, NGeneBio signed a business agreement with Agilent Technologies, Inc.'s Korea-based subsidiary, to expand the NGS precision diagnosis in South Korea and abroad.

Table of Contents

1. Executive Summary

2. Introduction

• 2.1 Oncology NGS: An Overview
  • 2.1.1 Definition of Oncology NGS
  • 2.1.2 Benefits of Oncology NGS
• 2.2 Oncology NGS Segmentation: An Overview
  • 2.2.1 Oncology NGS Segmentation

3. Global Market Analysis

• 3.1 Global Oncology NGS Market: An Analysis
  • 3.1.1 Global Oncology NGS Market: An Overview
  • 3.1.2 Global Oncology NGS Market by Value
  • 3.1.3 Global Oncology NGS Market by Technology
  • 3.1.4 Global Oncology NGS Market by Work Flow
  • 3.1.5 Global Oncology NGS Market by Application
  • 3.1.6 Global Oncology NGS Market by End User
  • 3.1.7 Global Oncology NGS Market by Region
• 3.2 Global Oncology NGS Market: Technology Analysis
  • 3.2.1 Global Oncology NGS Market by Technology: An Overview
  • 3.2.2 Global Targeted Sequencing & Resequencing Oncology NGS Market by Value
  • 3.2.3 Global Whole Exome Sequencing Oncology NGS Market by Value
  • 3.2.4 Global Whole Genome Sequencing Oncology NGS Market by Value
• 3.3 Global Oncology NGS Market: Work Flow Analysis
  • 3.3.1 Global Oncology NGS Market by Work Flow: An Overview
  • 3.3.2 Global Oncology NGS Sequencing Market by Value
  • 3.3.3 Global Oncology NGS Pre-sequencing Market by Value
  • 3.3.4 Global Oncology NGS Data Analysis Market by Value
• 3.4 Global Oncology NGS Market: Application Analysis
  • 3.4.1 Global Oncology NGS Market by Application: An Overview
  • 3.4.2 Global Screening Oncology NGS Market by Value
  • 3.4.3 Global Companion Diagnostics Oncology NGS Market by Value
  • 3.4.4 Global Other Diagnostics Oncology NGS Market by Value
• 3.5 Global Oncology NGS Market: End User Analysis
  • 3.5.1 Global Oncology NGS Market by End User: An Overview
  • 3.5.2 Global Laboratories Oncology NGS Market by Value
  • 3.5.3 Global Hospitals Oncology NGS Market by Value
  • 3.5.4 Global Clinics Oncology NGS Market by Value

4. Regional Market Analysis

• 4.1 North America Oncology NGS Market: An Analysis
  • 4.1.1 North America Oncology NGS Market: An Overview
  • 4.1.2 North America Oncology NGS Market by Value
  • 4.1.3 North America Oncology NGS Market by Region
  • 4.1.4 The US Oncology NGS Market by Value
  • 4.1.5 Canada Oncology NGS Market by Value
  • 4.1.6 Mexico Oncology NGS Market by Value
• 4.2 Europe Oncology NGS Market: An Analysis
  • 4.2.1 Europe Oncology NGS Market: An Overview
  • 4.2.2 Europe Oncology NGS Market by Value
  • 4.2.3 Europe Oncology NGS Market by Region
  • 4.2.4 Germany Oncology NGS Market by Value
  • 4.2.5 United Kingdom Oncology NGS Market by Value
  • 4.2.6 France Oncology NGS Market by Value
  • 4.2.7 Spain Oncology NGS Market by Value
  • 4.2.8 Italy Oncology NGS Market by Value
  • 4.2.9 Rest of Europe Oncology NGS Market by Value
• 4.3 Asia Pacific Oncology NGS Market: An Analysis
  • 4.3.1 Asia Pacific Oncology NGS Market: An Overview
  • 4.3.2 Asia Pacific Oncology NGS Market by Value
  • 4.3.3 Asia Pacific Oncology NGS Market by Region
  • 4.3.4 China Oncology NGS Market by Value
  • 4.3.5 Japan Oncology NGS Market by Value
  • 4.3.6 India Oncology NGS Market by Value
  • 4.3.7 South Korea Oncology NGS Market by Value
  • 4.3.8 Rest of Asia Pacific Oncology NGS Market by Value
• 4.4 Rest of the World Oncology NGS Market: An Analysis
  • 4.4.1 Rest of the World Oncology NGS Market: An Overview
  • 4.4.2 Rest of the World Oncology NGS Market by Value

5. Impact of COVID-19

• 5.1 Impact of COVID-19 on Global Oncology NGS Market
• 5.2 Post COVID-19 Impact on Global Oncology NGS Market

6. Market Dynamics

• 6.1 Growth Drivers
  • 6.1.1 Rising Cancer Incidence
  • 6.1.2 Growing Healthcare Expenditure
  • 6.1.3 Government Initiatives
  • 6.1.4 Cost Reduction
• 6.2 Challenges
  • 6.2.1 Complex Data Analysis and Interpretation
  • 6.2.2 Ethical and Privacy Concerns
• 6.3 Market Trends
  • 6.3.1 Integration with AI and Bioinformatics
  • 6.3.2 Liquid Biopsies Innovations
  • 6.3.3 Increased Focus on Personalized Medicine
  • 6.3.4 Rise of Companion Diagnostics
  • 6.3.5 Advancements in Sequencing Technologies
  • 6.3.6 Increased R&D Investments
  • 6.3.7 Decentralization of NGS Testing

7. Competitive Landscape

• 7.1 Global Newborn Screening Market: Competitive Landscape
• 7.2 Global Newborn Screening Market: Recent Developments

8. Company Profiles

• 8.1 Thermo Fisher Scientific Inc.
  • 8.1.1 Business Overview
  • 8.1.2 Operating Segments
  • 8.1.3 Business Strategy
• 8.2 Agilent Technologies, Inc.
  • 8.2.1 Business Overview
  • 8.2.2 Operating Segments
  • 8.2.3 Business Strategy
• 8.3 Qiagen
  • 8.3.1 Business Overview
  • 8.3.2 Sales by Product Group
  • 8.3.3 Business Strategy
• 8.4 Illumina, Inc.
  • 8.4.1 Business Overview
  • 8.4.2 Operating Segments
  • 8.4.3 Business Strategy
• 8.5 Roche Holdings AG
  • 8.5.1 Business Overview
  • 8.5.2 Operating Segments
  • 8.5.3 Business Strategy
• 8.6 Revvity, Inc.
  • 8.6.1 Business Overview
  • 8.6.2 Operating Segments
  • 8.6.3 Business Strategy
• 8.7 Pacific Biosciences of California, Inc.
  • 8.7.1 Business Overview
  • 8.7.2 Revenue by Geography
  • 8.7.3 Business Strategy
• 8.8 Myriad Genetics, Inc.
  • 8.8.1 Business Overview
  • 8.8.2 Business Strategy
• 8.9 Oxford Nanopore Technologies
  • 8.9.1 Business Overview
  • 8.9.2 Business Strategy
• 8.10 BGI Group (Beijing Genomics)
  • 8.10.1 Business Overview
  • 8.10.2 Business Strategy
• 8.11 Caris Life Sciences
  • 8.11.1 Business Overview
  • 8.11.2 Business Strategy